Cardiovascular risk factors and venous thromboembolism: A meta-analysis

Circulation

Volumn 117, Issue 1, 2008, Pages 93-102

  Ageno, Walter ^a,f   Becattini, Cecilia ^b   Brighton, Timothy ^c   Selby, Rita ^d   Kamphuisen, Pieter W ^e  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Atherosclerosis; Risk factors; Thrombosis; Veins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DIABETES MELLITUS; EMBASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEDLINE; PREVALENCE; PRIORITY JOURNAL; SMOKING; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; DATABASES, BIBLIOGRAPHIC; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SMOKING; VENOUS THROMBOEMBOLISM;

EID: 37349104557     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.709204     Document Type: Article

References (66)

1. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med. 2002;162:1182-1189.
2. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AWA, Prins MH, Girolami A. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435-1441.
3. Becattini C, Agnelli G, Prandoni P, Silingardi M, Salvi R, Taliani MR, Poggio R, Imberti D, Ageno W, Pogliani E, Porro F, Casazza F. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J. 2005;26:77-83.
4. Prandoni P, Ghirarduzzi A, Prins MH, Pengo V, Davidson BL, Sorensen H, Pesavento R, Iotti M, Caviglia E, Iliceto S, Pagnan A, Lensing AWA. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost. 2006;4:1891-1896.
5. van der Hagen PB, Folsom AR, Jenny NS, Heckbert SR, O'Meara ES, Reich LM, Rosendaal FR, Cushman M. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost. 2006;4:1903-1908.
6. Reich LM, Folsom AR, Key NS, Boland LL, Heckbert SR, Rosamond WD, Cushman M. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost. 2006;4:1909-1913.
7. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the Study of Men Born in 1913". Arch Intern Med. 1999;159:1886-1890.
8. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415-3420.
9. Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia. 2005;48:1017-1021.
10. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642-645.
11. Vaya A, Mira Y, Ferrando F, Contreras M, Estelles A, Espana F, Corella D, Aznar J. Hyperlipidemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol. 2002;118:255-259.
12. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112:893-899.
13. Doggen CJM, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-1975.
14. Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, Crowther M, Venco A. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost. 2006;4:1914-1918.
15. Ray J. Dyslipidemia, statins and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med. 2003;9:378-384.
16. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz GS, Barnathan BS, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-3561.
17. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
18. Homocysteine Studies Collaboration. Homocysteine and the risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
19. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:292-299.
20. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G, for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine, 3: measures of observer variability (kappa statistic). Can Med Assoc J. 2004;171:1369-1373.
21. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987;126:161-169.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
24. Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol. 1979;110:188-195.
25. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969;90:365-380.
26. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol. 2005;162:975-982.
27. Simmonds JP, O'Malley BP, Maskill MR. Beta-thromboglobulin levels in relation to myocardial infarction: preliminary observations. Acta Haematol. 1980;64:172-175.
28. Manfredini R, Gallerani M, Boari B, Salmi R, Mehta RH. Seasonal variation in onset of pulmonary embolism is independent of patients' underlying risk comorbid conditions. Clin Appl Thromb Hemost. 2004;10:39-43.
29. Yoo HHB, De Paiva SAR, De Arruda Silveira, Queluz TT. Logistic regression analysis of potential prognostic factors for pulmonary thromboembolism. Chest. 2003;123:813-821.
30. Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, Gherardi G, Feinleib M. Risk factors for pulmonary embolism: the Framingham study. Am J Med. 1983;74:1023-1028.
31. Whiteman MK, Cui Y, Flaws JA, Espeland M, Bush TL. Low fibrinogen level: a predisposing factor for venous thromboembolic events with hormone replacement therapy. Am J Hematol. 1999;61:271-273.
32. Beaumont V, Lemort N, Beaumont JL. Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases. Eur Heart J. 1991;12:1219-1224.
33. Vaya A, Mira Y, Martinez M, Villa P, Ferrando F, Estelles A, Corella D, Aznar J. Biological risk factors for deep vein thrombosis. Clin Hemorheol Microcirc. 2002;26:41-53.
34. Oestrogen plus progestin hormone replacement therapy increases venous thrombosis in postmenopausal women. Evidence-Based Healthcare Public Health. 2005;9:159-160.
35. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999;180:S357-S363.
36. Poulter NR, Meirik O, Chang CL, Farley TMM, Marmot MG. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575-1582.
37. Palosuo T, Virtamo J, Haukka J, Taylor PR, Aho K, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men: a nested case-control study. Thromb Haemost. 1997;78:1178-1182.
38. Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res. 1997;88:67-73.
39. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost. 1999;82:1218-1221.
40. McColl MD, Sattar N, Ellison J, Tait RC, Walker ID, Packard CJ, Greer IA. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis. 2000;11:225-229.
41. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2000;5:265-274.
42. Segui R, Estelles A, Mira Y, Espana F, Villa P, Falco C, Vaya A, Grancha S, Ferrando F, Aznar J. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000;111:122-128.
43. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187-196.
44. Abdollahi M, Cushman M, Rosendaal FR. Obesity: Risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493-498.
45. Gonzalez-Ordonez AJ, Fernandez-Carreira JM, Fernandez-Alvarez CR, Venta Obaya R, Macias Robles RD, Gonzalez Franco A, Arias Garcia MA. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica. 2003;88:1035-1043.
46. Paganin F, Bourde A, Yvin J-L, Genin R, Guijarro JL, Bourdin A, Lasalle C. Venous thromboembolism in passengers following a 12-h flight: a case-control study. Aviat Space Environ Med. 2003;74:1277-1280.
47. Zamani A, Omrani GR, Lankarani KB. Hyperhomocysteinaemia, hyperlipidaemia and risk of venous thromboembolism in Shiraz. East Mediterr Health J. 2003;9:935-943.
48. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR, for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573-1580.
49. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, Nordestgaard BG. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood. 2004;104:3046-3051.
50. Sydney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP Jr. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004;70:3-10.
51. Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734-742.
52. Bova C, Marchiori A, Noto A, Rossi V, Daniele F, Santoro C, Ricchio R, De Lorenzo R, Umbaca R, Prandoni P. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism: a retrospective cohort study. Thromb Haemost. 2006;96:132-136.
53. Sundell B, Nilsson TK, Råndy M, Hallsmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol. 1989;42:719-723.
54. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
55. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181-2188.
56. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476-1485.
57. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282-1291.
58. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance: evidence for a common antecedent? Diabetes Care. 1999;22(suppl):C25-C30.
59. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;15:897-907.
60. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Monzani G. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992;67:643-654.
61. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults: the ARIC study: Atherosclerosis Risk in Communities. Obes Res. 2000;8:279-286.
62. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Roosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-1975.
63. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes. 2003;52:1248-1255.
64. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, Griffin JH. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609-1614.
65. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(suppl I):I-4-I-8.
66. Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost. 2006;4:1925-1927.